The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.

Original title: “BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial”

RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.

Original title: “Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’”

A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.

Original title: “ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3”

Invikafusp alfa, a first-in-class dual T cell agonist, showed an objective response in various types of cancer, particularly among patients who did not respond to previous checkpoint inhibitor therapy.

Original title: “ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2”

After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.

Original title: “FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns”

EMA’s Emergency Task Force (ETF) and the African Medicines Agency (AMA) have published a joint position paper to support the timely start of clinical trials for potential…

Original title: “AMA and EMA issue joint guidance on Ebola vaccine development”